Insider Selling: AnaptysBio (NASDAQ:ANAB) Director Sells $249,350.00 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director Hollings Renton sold 5,000 shares of the stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $49.87, for a total transaction of $249,350.00. Following the sale, the director directly owned 10,995 shares in the company, valued at approximately $548,320.65. This represents a 31.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

AnaptysBio Stock Performance

Shares of NASDAQ ANAB opened at $48.53 on Monday. AnaptysBio, Inc. has a 1-year low of $19.65 and a 1-year high of $72.36. The company has a 50-day moving average of $55.04 and a two-hundred day moving average of $58.58. The company has a market cap of $1.45 billion, a PE ratio of 9.04 and a beta of 0.76.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Monday, September 21st. The biotechnology company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $5.57. The business had revenue of $27.49 million during the quarter, compared to analyst estimates of $14.06 million. AnaptysBio had a net margin of 82.37% and a return on equity of 112.00%. During the same quarter last year, the business posted ($1.30) earnings per share. As a group, equities research analysts forecast that AnaptysBio, Inc. will post -1.3 earnings per share for the current year.

Institutional Trading of AnaptysBio

A number of large investors have recently made changes to their positions in the company. First Light Asset Management LLC raised its stake in AnaptysBio by 2.9% during the 2nd quarter. First Light Asset Management LLC now owns 582,004 shares of the biotechnology company’s stock worth $39,285,000 after buying an additional 16,573 shares during the period. Squarepoint Ops LLC grew its stake in AnaptysBio by 21.2% in the second quarter. Squarepoint Ops LLC now owns 324,446 shares of the biotechnology company’s stock valued at $21,900,000 after acquiring an additional 56,743 shares during the period. Arizona State Retirement System increased its holdings in shares of AnaptysBio by 13.5% in the second quarter. Arizona State Retirement System now owns 4,363 shares of the biotechnology company’s stock worth $295,000 after acquiring an additional 518 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of AnaptysBio during the second quarter worth about $1,164,000. Finally, Irenic Capital Management LP bought a new position in shares of AnaptysBio during the 2nd quarter valued at about $4,755,000.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ANAB. Cantor Fitzgerald reiterated an “overweight” rating on shares of AnaptysBio in a research report on Tuesday, September 22nd. Wall Street Zen cut shares of AnaptysBio from a “buy” rating to a “hold” rating in a research report on Sunday. Scotiabank lowered shares of AnaptysBio to a “hold” rating and set a $70.00 price objective on the stock. in a report on Tuesday, August 25th. Leerink Partners reduced their price objective on shares of AnaptysBio from $90.00 to $81.00 and set an “outperform” rating on the stock in a research note on Wednesday, September 23rd. Finally, Wolfe Research reaffirmed an “outperform” rating and set a $78.00 target price on shares of AnaptysBio in a report on Monday, August 31st. Thirteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $77.79.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for inflammatory and autoimmune diseases. The company uses its antibody discovery and engineering capabilities to identify therapies designed to modulate immune-system targets involved in disease.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody designed to target CD200R1, a receptor involved in regulating immune-cell activity. The company has evaluated rosnilimab in inflammatory and autoimmune conditions, including rheumatoid arthritis and ulcerative colitis.